ANDA 206877, held by Aurobindo Pharma. Omeprazole Magnesium.
As of Nov 16, 2026, ANDA 206877 (Omeprazole Magnesium), held by Aurobindo Pharma, was first approved by FDA on Jun 6, 2018, with 4 approved supplements and 0 published complete response letters.
Use treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 6, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Omeprazole MagnesiumEQ 20MG BASE · tablet, delayed release;oral | Omeprazole Magnesium | OTC |
| Nov 8, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 8, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 8, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 8, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 6, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters